Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6851161 | 1.00 | PPM1D (0.31) | PPM1DGRIN1GRIN2B | |
| SCHEMBL4159405 | 1.00 | PPM1D (0.31) | PPM1DGRIN1GRIN2B | |
| SCHEMBL7150696 | 0.94 | PPM1D (0.33) | PPM1D | |
| SCHEMBL7150700 | 0.94 | PPM1D (0.33) | PPM1D | |
| SCHEMBL20244226 | 0.81 | CYP19A1 (0.40) | — | |
| SCHEMBL21613284 | 0.81 | CYP19A1 (0.40) | — | |
| SCHEMBL13317271 | 0.80 | PPM1D (0.32) | PPM1DGRIN1GRIN2B | |
| SCHEMBL7152133 | 0.77 | PPM1D (0.35) | PPM1D | |
| SCHEMBL17180453 | 0.75 | CYP19A1 (0.33) | — | |
| SCHEMBL13392638 | 0.73 | CYP19A1 (0.40) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
| EP-0805682-B1 | DERMATOLOGICAL USE OF VITAMIN D DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-5827883-A | TOPICAL DRUG DELIVERY; SIDE EFFECT REDUCTION | HOFFMANN-LA ROCHE INC. (US) | 1998-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | VDR, CYP2R1, CYP24A1 | PPM1D 4604/4885GRIN1 3292/4885GRIN2B 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.